Background {#Sec1}
==========

Hereditary transthyretin (TTR) amyloidosis (ATTRv amyloidosis), which is caused by mutations in the *TTR* gene, is an inherited systemic disorder characterized by extracellular amyloid deposits. Patients with ATTRv amyloidosis develop systemic symptoms such as sensorimotor neuropathy, autonomic dysfunction, cardiomyopathy, gastrointestinal dysfunction, renal failure, and ocular disorders \[[@CR1]\]. To date, more than 140 different mutations in the *TTR* gene have been reported, most of which have been associated with ATTRv amyloidosis. Of the pathogenic TTR mutations, Val30Met is most frequently found worldwide \[[@CR2], [@CR3]\].

TTR is a plasma protein, which is mainly synthesized in the liver, and acts as a transporter of thyroxine and retinol-binding protein with vitamin A. In the bloodstream, TTR forms a homotetramer with a dimer-of-dimers configuration. TTR mutations cause destabilization of TTR tetramers, which is believed to be a crucial step in formation of TTR amyloid \[[@CR4]\]. Regarding this mutation, late-onset patients from non-endemic areas show distinctive clinical features from early-onset patients from conventional endemic foci \[[@CR5]\]. Patients with ATTRv amyloidosis, particularly late-onset cases, tend to be initially misdiagnosed as having other diseases \[[@CR6]\].

Mass spectrometry (MS) is a powerful tool that can detect small molecular changes in proteins. Because the molecular masses of variant TTRs with amino acid exchanges differ from that of wild-type (WT) TTR, we developed diagnostic methods to detect variant TTRs in serum samples by means of several different mass spectrometric analyses such as matrix-assisted laser desorption-ionization time-of-flight (MALDI-TOF) MS with immunoprecipitated (IP) serum TTR (IP-MALDI) \[[@CR7]--[@CR9]\], electrospray ionization (ESI) MS with IP serum TTR (IP-ESI) \[[@CR10]--[@CR12]\], and surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) MS ProteinChip system \[[@CR13], [@CR14]\]. Although those methods are valuable for screening ATTRv amyloidosis and double-checking TTR variants in addition to genetic testing of the *TTR* gene, they require significant time to analyze variant TTRs, and they also sometimes fail to detect TTRs because of technical difficulties related to the cumbersome immunoprecipitation with anti-TTR antibodies.

Here, we developed a new simple and reliable mass spectrometric method for ATTRv amyloidosis screening in which we can directly detect variant TTRs in serum samples without pre-purification by using MALDI-TOF MS (direct MALDI).

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Between April 2015 and March 2017, we examined 288 serum samples obtained from patients who were clinically suspected of having amyloidosis. Table [1](#Tab1){ref-type="table"} provides detailed information about serum samples obtained from 42 patients with ATTRv amyloidosis.Table 1Variant TTRs detected in 42 serum samples obtained from 42 patients with ATTRv amyloidosis by means of the direct MALDI methodPatient numberTTR mutationDetection of variant TTR peaksTheoretical mass changes (*m/z*)Measured mass changes (*m/z*)1Val30Met++  32.06+  31.952Val30Met++  32.06+  31.623Val30Met++  32.06+  31.584Val30Met++  32.06+  31.305Val30Met++  32.06+  32.086Val30Met++  32.06+  31.217Val30Met++  32.06+  32.518Val30Met++  32.06+  31.979Val30Met++  32.06+  31.2010Val30Met++  32.06+  31.5311Val30Met++  32.06+  33.2212Val30Met++  32.06+  32.0713Val30Met++  32.06+  31.7714Val30Met++  32.06+  32.4515Val30Met++  32.06+  31.3316Val30Met++  32.06+  32.4617Val30Met++  32.06+  30.7518Val30Met++  32.06+  31.2919Val30Met++  32.06+  32.7320Val30Met++  32.06+  32.5721Val30Met++  32.06+  31.2222Val30Met++  32.06+  31.5423Val30Met++  32.06+  31.3524Val30Met++  32.06+  31.8225Val30Met++  32.06+  31.7226Val30Met++  32.06+  31.3027Val28Ser+- 12.06- 13.2528Val28Met++  32.06+  32.0529Gly47Arg++  99.13+  98.7230Thr49Ser+- 14.03- 13.8331Thr49Ile++  12.05+  8.7932Gly53Glu++  72.06+  71.0233Thr60Ala+- 30.03- 29.2234Glu61Lys--- 0.94ND35Glu61Lys--- 0.94ND36Glu61Lys--- 0.94ND37Lys80Arg++  28.01+  27.7638Gly83Arg++  99.13+  98.7739Glu89Gln--- 9.90ND40Ala97Gly+- 14.02- 13.5541Tyr114Ser+- 76.10- 78.9842Tyr114Cys+- 60.03- 59.56*Abbreviation*: *ND* not detected

Direct MALDI method to detect variant TTRs in serum samples {#Sec4}
-----------------------------------------------------------

Serum samples (2 μL each) were diluted 100-fold with distilled water. Aliquots of 20 μL of the diluted samples were mixed with 1 μL of 100 mmol/L dithiothreitol solution in 25 mmol/L NH~4~HCO~3~, and then samples were incubated at 95 °C for 5 min. Aliquots of 1 μL of the incubated samples were mixed with 1 μL of 20 mg/ml 2,5-dihydroxybenzoic acid solution (Bruker, Billerica, MA, USA), and then 1 μL aliquots of the mixed samples were loaded onto the target plate and were air dried at room temperature. The samples were analyzed in a mass range between 1000 and 20,000 Da with MALDI-TOF MS (Autoflex Speed; Bruker) (Fig. [1](#Fig1){ref-type="fig"}). The ion peaks were calibrated with insulin (average m/z: 5734.51), ubiquitin I (average m/z: 8565.76), cytochrome c (average m/z: 12360.97) and myoglobin (average m/z: 16952.30) (Protein Calibration Standard I; Bruker).Fig. 1Schematic overview of the direct MALDI method to detect variant TTRs in serum samples. DTT, dithiothreitol; DHB, 2,5-dihydroxybenzoic acid

Genetic testing {#Sec5}
---------------

We analyzed the *TTR* genes as previously described \[[@CR15]\].

Results {#Sec6}
=======

Simple and rapid detection of variant TTRs in serum samples from patients with ATTRv amyloidosis by using MALDI-TOF MS without pre-purification {#Sec7}
-----------------------------------------------------------------------------------------------------------------------------------------------

By using a one-step procedure without pre-purification (direct MALDI), within 30 min we successfully detected variant TTR Val30Met in addition to WT TTR in serum samples from ATTRv amyloidosis patients with a heterozygous TTR Val30Met mutation. The direct MALDI method demonstrated that the measured mass shift between variant TTR Val30Met and WT TTR was 32 Da, which was consistent with the theoretical mass shift.

We next analyzed 42 serum samples obtained from 42 patients with ATTRv amyloidosis (Table [1](#Tab1){ref-type="table"}). On the basis of genetic analysis of the *TTR* gene, these patients with ATTRv amyloidosis had 15 different TTR mutations: Val30Met, Val28Ser, Val28Met, Gly47Arg, Thr49Ser, Thr49Ile, Gly53Glu, Thr60Ala, Glu61Lys, Lys80Arg, Gly83Arg, Glu89Gln, Ala97Gly, Tyr114Ser, and Tyr114Cys (Table [1](#Tab1){ref-type="table"}). With the direct MALDI method, we detected variant TTRs in 38 (91%) of 42 serum samples (Fig. [2](#Fig2){ref-type="fig"}a, Table [1](#Tab1){ref-type="table"}). Direct MALDI could not distinguish between two variant TTRs---Glu61Lys and Glu89Gln. The theoretical mass shift difference between Glu61Lys and Glu89Gln variant TTRs and WT TTR were 0.94 and 0.99 *m/z*, respectively (Table [1](#Tab1){ref-type="table"}), which were thought to be insufficient to separate these variant TTRs from WT TTR by direct MALDI. We detected only WT TTR in all 246 serum samples obtained from 246 patients without TTR mutations by using direct MALDI.Fig. 2Detection of variant TTRs by using direct MALDI. **a** Mass peaks of TTRs in serum samples obtained by means of direct MALDI. Arrows point to variant TTR peaks. **b** Correlation between measured and theoretical mass shifts (*y* = 0.9937*x* + 0.0834; r^2^ = 0.9969)

Correlation between measured and theoretical mass shifts of variant TTRs from WT TTR in serum samples from patients with ATTRv amyloidosis with different TTR mutations {#Sec8}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

We measured the mass shifts of variant TTRs by the direct MALDI method and compared them with the theoretical mass changes. Direct MALDI revealed a highly significant correlation between measured and theoretical mass shifts from WT TTR in serum samples from ATTRv amyloidosis patients with different TTR mutations (r^2^ = 0.9969; Fig. [2](#Fig2){ref-type="fig"}b).

Discussion {#Sec9}
==========

Using this direct MALDI method, we rapidly detected variant TTRs in serum samples obtained from patients with ATTRv amyloidosis. We found a highly significant correlation between measured and theoretical mass shifts from WT TTR in serum samples from these patients.

Development of disease-modifying therapies for ATTRv amyloidosis has made dramatic advances. Liver transplantation (LT) has been performed to halt the progression of ATTRv amyloidosis. LT can lead to mutant TTR synthesized by a diseased liver being replaced with WT TTR produced by the healthy liver graft \[[@CR16], [@CR17]\]. In addition, TTR tetramer stabilizers such as tafamidis and diflunisal were developed to prevent dissociation of the TTR tetramer to monomers and to inhibit progression of this disease \[[@CR18], [@CR19]\]. Clinical studies have also revealed that gene-silencing therapies, such as the use of small interfering RNA and antisense oligonucleotides that target the *TTR* gene, dramatically reduced disease-causing TTR expression by the liver and significantly improved symptoms of patients with ATTRv amyloidosis \[[@CR20], [@CR21]\]. Early diagnosis of ATTRv amyloidosis is becoming more important so that these new disease-modifying therapies may be utilized earlier.

To detect variant TTR in serum samples from patients in a one-step procedure, we developed a new direct MALDI method, which did not require pre-purification such as immunoprecipitation with anti-TTR antibodies. This method required only 30 min to obtain results. Other mass spectrometric methods, such as IP-MALDI, IP-ESI, and SELDI, needed significant time to detect variant TTRs in serum samples because of cumbersome pre-purification such as immunoprecipitation with anti-TTR antibodies or use of the ProteinChip system (Table [2](#Tab2){ref-type="table"}) \[[@CR7]--[@CR14]\]. Direct MALDI is thus a simple means of detecting TTR variants for clinical screening compared with other methods.Table 2Comparison of different mass spectrometric methods to detect variant TTRs in serum samplesParameterIP-ESI \[[@CR10], [@CR11]\]IP-MALDI \[[@CR7]--[@CR9]\]SELDI-TOF MS \[[@CR13], [@CR14]\]Direct MALDI (the present study)Immunoprecipitation++----ProteinChip system----+--Running costLowLowHighLowDetection time2 days2 days3 h30 minMinimum mass difference that can be identified in each system14 Da13 Da15 Da12 Da

Our direct MALDI method demonstrated a high sensitivity (91%) for detection of variant TTRs in our patients with various TTR mutations, although it failed to detect the rare TTR variants Glu61Lys and Glu89Gln, whose mass differences from WT TTR were 0.94 and 0.99 *m/z*, respectively. We should therefore note that direct MALDI could not distinguish mass differences of rare variant TTRs with small mass shifts, that is, TTR variants whose mass differences from WT TTR were less than 12 Da (Table [1](#Tab1){ref-type="table"}). Direct MALDI succeeded, however, in detecting most variant TTRs, including the common Val30Met TTR. Direct MALDI may thus be useful for the screening of ATTRv amyloidosis.

Genetic testing is the most reliable tool for diagnosing inherited diseases. However, genetic testing usually takes a long time and is not infallible because of human errors \[[@CR22]\]. Therefore, to avoid misdiagnosis of ATTRv amyloidosis, we need an accurate system for double-checking results. Direct MALDI therefore promises to be a valuable tool for double-checking the diagnosis of ATTRv amyloidosis.

Conclusions {#Sec10}
===========

In conclusion, direct MALDI is a simple and quick method to detect serum variant TTRs and is useful for screening of ATTRv amyloidosis.
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